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Abstract A dopamine D2Short receptor:GKo fusion protein was
expressed in Sf9 cells using the baculovirus expression system.
[3H]Spiperone bound to D2Short :GKo with a pKdW10. Dopamine
stimulated the binding of [35S]guanosine-5P-O-(3-thio)triphos-
phate (GTPQS) to D2Short :GKo expressed with GL1Q2 (Emaxs
460%; pEC50 5.431 0.06). Most of the putative D2 antagonists
behaved as inverse agonists (suppressing basal [35S]GTPQS bind-
ing) at D2Short :GKo/GL1Q2 although (3)-sulpiride and ziprasi-
done were neutral antagonists. Competition of [3H]spiperone
binding by dopamine and 10,11-dihydroxy-N-n-propylnorapo-
morphine revealed two binding sites of di¡erent a⁄nities, even
in the presence of GTP (100 WM). The D2Short :GKo fusion pro-
tein is therefore a good model for characterising D2 receptors.
8 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
The mechanisms by which ligands interact with and activate
G protein-coupled receptors (GPCR) remain poorly under-
stood. This is partly due to the fact that several parameters
can a¡ect the response observed upon GPCR stimulation by
an agonist, including the number of receptors (R), the number
of G proteins (G) and the R/G ratio [1,2]. Further complexity
arises from the ¢nding that a single GPCR can activate dis-
tinct G proteins within the same cell system [3,4]. Fusion
proteins, which covalently link the receptor to the GK subunit
of the G protein, have been introduced as an alternative ap-
proach which might help in understanding the mechanisms of
interaction and activation of receptors and G proteins by
di¡erent ligands, without the potential confounding e¡ect of
di¡erences in R/G ratio. Hence fusion proteins between di-
verse GPCRs and their cognate G proteins have been used to
study receptor/G protein interaction [5^7].
The D2 dopamine receptor, a member of the dopamine
receptor family (which comprises ¢ve receptors, D1^D5), is a
prototypical GPCR, which interacts with and signals via G
proteins of the Gi=o family. Alternative splicing of the D2
receptor mRNA results in two isoforms of the receptor,
termed D2S (short) and D2L (long) [8]. The D2S receptor
was shown to couple preferentially to Gi1 over Gi2 when ex-
pressed in Sf9 cells [9] and distinct roles for G protein sub-
units in the modulation of cAMP accumulation and calcium
mobilisation by D2 receptors were described [10,11]. It was
also suggested that the 29 amino acid insert of D2L might
confer selectivity for interaction with Gi2 [12]. Recently, we
reported the regulation of G protein selectivity by agonists for
the rat and for the human D2L receptor using the baculovirus
expression system [13,14]. These observations suggest di¡er-
ences in the molecular mechanisms of the interaction of the
D2 receptors with di¡erent G proteins, which may account for
di¡erent signalling and therefore di¡erent functions. Further
insights into mechanisms of action of agonists at GPCRs may
be obtained using the receptor^G protein fusion strategy.
However, no report has yet described a functional fusion pro-
tein between the D2 dopamine receptor and a G protein.
The aim of this study was to analyse the pharmacological
pro¢le of a fusion protein involving the human D2S receptor
and a rat GKo subunit of the G protein, using the baculovirus
expression system. Our results show that such a construct
presents characteristics similar to those of the D2 receptor
expressed in other heterologous systems. In addition, our
data also suggest that the D2S receptor engaged in a fusion
with the GKo subunit can exhibit constitutive activity, as illus-
trated by the inverse agonist activity of some putative D2
receptor antagonists.
2. Materials and methods
2.1. Materials
Bromocriptine, (+)-butaclamol, clozapine, dopamine, haloperidol,
(3)-quinpirole, m-tyramine, p-tyramine, S-(3)-3-(3-hydroxyphenyl)-
N-propylpiperidine (3-PPP), R-(+)-3-PPP, R-(3)-10,11-dihydroxy-N-
n-propylnorapomorphine (NPA) were purchased from Sigma (St.
Louis, MO, USA). Aripiprazole and ziprasidone were generous gifts
from Psychiatry CEDD, GlaxoSmithKline (Harlow, UK). (+)-AJ76
and (+)-UH232 were from Tocris (Bristol, UK). [3H]Spiperone (15^30
Ci/mmol) and [35S]guanosine-5P-O-(3-thio)triphosphate (GTPQS, 1099^
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1148 Ci/mmol) were from Amersham International (Buckinghamshire,
UK). All other reagents were obtained as indicated.
2.2. Construction of D2S :GKo fusion protein
The D2S :GKo fusion protein was created by mutating the human
D2S dopamine receptor stop codon into an alanine residue, followed
by two additional alanine residues, constituting a NotI restriction site.
Similarly, a NotI site was inserted at the ATG codon of the rat GKo
protein sequence. The fusion was made following NotI restriction and
ligation. In addition, Cys351 of the rat GKo protein was mutated into
an Ile (TGT codon into ATT). All the mutations were generated by
polymerase chain reaction (PCR), using the Quick Change Site-Di-
rected Kit (Stratagene). The resulting fusion protein sequence was
cloned into a pCR3.1 vector (Invitrogen). The construct was fully
sequenced to con¢rm the nucleotide sequence.
2.3. Construction and isolation of recombinant baculovirus
The cDNA fragment containing the D2S :GKo sequence was re-
moved from plasmid pCR3.1 using an EcoRI restriction site. The
cDNA sequence was then subcloned into the transfer vector
pVL1392 (PharMingen) and cotransfected with BaculoGold0 DNA
in Sf9 cells, using the BaculoGold1 transfection kit (PharMingen).
The recombinant baculoviruses were puri¢ed and ampli¢ed by serial
infections of Sf9 cells. The viruses expressing the human G protein L1
and Q2 subunits were generously donated by T. Kozasa (University of
Illinois, Chicago, IL, USA). All viruses were subjected to PCR to
verify their purity and their titres were determined using plaque as-
says.
2.4. Cell culture
Sf9 cells were grown in suspension in TC-100 medium supple-
mented with 10% foetal calf serum and 0.1% pluronic F-680. The
cells were maintained at a density of 0.5^2.5U106 cells/ml and were
passaged every 2^3 days. For infections, cells were seeded at a density
of 0.6U106 cells/ml and infected when they reached log phase growth,
i.e. at a density of about 1U106 cells/ml. Infections were carried out
with D2S :GKo baculovirus alone using a multiplicity of infection
(MOI) of 10 or a combination of D2S :GKo with GL1 and GQ2 bacu-
loviruses. In this latter case the MOIs of the baculoviruses used were
10/7/7 for D2S :GKo/GL1/GQ2, respectively. Cells were harvested 48 h
post infection. Where indicated, Bordetella pertussis toxin (PTX) was
added to the culture medium at a concentration of 100 ng/ml for 18 h
prior to cell harvesting.
2.5. Membrane preparation
All operations were carried out at 0^4‡C. Cells were collected by
centrifugation (1700Ug, 10 min, 4‡C) and resuspended in 15 ml of
bu¡er (20 mM HEPES, 6 mM MgCl2, 1 mM EDTA, 1 mM EGTA,
pH 7.4). Cell suspensions were then homogenised using an Ultra
Turrax at setting 4^5 for 20 s. The homogenate was centrifuged at
1700Ug for 10 min and the supernatant was collected and centrifuged
at 48 000Ug for 1 h at 4‡C. The resulting pellet was resuspended in
bu¡er and stored at 380‡C in aliquots of 500 Wl. The protein con-
centration was determined by the method of Lowry et al. [15], using
bovine serum albumin as standard.
2.6. Ligand binding assays
[3H]Spiperone saturation binding experiments were performed as
described previously [14]. Brie£y, eight concentrations of radioligand
were used, ranging from approximately 10 pM to 2 nM. The reaction
was started by the addition of membrane proteins and incubated for
3 h at 25‡C. Reactions were terminated by rapid ¢ltration through
Whatman GF/C glass ¢bre ¢lters using a Brandel cell harvester fol-
lowed with four washes of 3 ml of ice-cold phosphate-bu¡ered saline
(PBS: 140 mM NaCl, 10 mM KCl, 1.5 mM KH2PO4, 8 mM
Na2HPO4) and the radioactivity trapped on the ¢lters was determined
by liquid scintillation spectrometry. Non-speci¢c binding was de¢ned
in the presence of 3 WM (+)-butaclamol. For [3H]spiperone competi-
tion binding experiments, a range of concentrations of competing li-
gand were incubated with a ¢xed concentration of radioligand (typi-
cally 0.45 nM) and the reactions were started and terminated as in
[14].
2.7. [35S]GTPQS binding assays
Cell membranes (15^25Wg) were incubated in triplicate with 1 WM
GDP and increasing concentrations of agonist in a ¢nal volume of 0.9
ml bu¡er (20 mM HEPES, 10 mM MgCl2, 100 mM NaCl, pH 7.4) for
30 min at 30‡C. 0.1 ml of [35S]GTPQS was added to a ¢nal concen-
tration of 100 pM and the incubation continued for a further 30 min.
Basal level of [35S]GTPQS binding was de¢ned as that in the absence
of agonist. Incubations were terminated by rapid ¢ltration through
Whatman GF/C glass ¢bre ¢lters using a Brandel cell harvester with
four washes of 3 ml of PBS and radioactivity determined as above.
2.8. Analysis of data
Data were analysed using the computer program GraphPad Prism
(GraphPad Software). [3H]Spiperone saturation binding curves were
¢tted best by a one binding site model from which the Bmax (receptor
expression level) and Kd (dissociation constant for [3H]spiperone)
were derived. Data from competition experiments were ¢tted to two
binding site and one binding site models, and the best ¢t was deter-
mined using an F-test. IC50 values of competitors were derived from
this analysis and the Ki values (inhibition constants) were calculated
using the method of [16]. Concentration^response curves for agonist
and inverse agonist e¡ects on [35S]GTPQS binding were analysed by
non-linear least squares regression analysis using a sigmoidal concen-
tration/response relationship with a Hill coe⁄cient of 1 and EC50 (or
IC50 for inverse agonists) and Emax (maximum e¡ect) values were
derived from this analysis. Results are given as meanTS.E.M. of
the indicated number of experiments.
3. Results
3.1. Expression of D2S :GKo fusion protein in Sf9 cells
Expression of the D2S :GKo fusion protein in Sf9 cells was
assessed using [3H]spiperone saturation binding assays. As
shown in Fig. 1, [3H]spiperone labelled a saturable population
of receptors in membranes prepared from Sf9 cells expressing
D2S :GKo with or without GL1Q2 subunits. The Bmax obtained
amounted to 3290T 570 and 2730T 230 fmol/mg of protein
for the fusion protein alone and the fusion protein co-ex-
pressed with GL1Q2, respectively. [3H]Spiperone had a high
a⁄nity for the D2S :GKo fusion protein expressed alone or
with GL1Q2 subunits, with pKd values of 9.83T 0.06 (Kd 0.15
nM) and 9.93 T 0.05 (Kd 0.12 nM), meanTS.E.M., ns 7, for
D2S :GKo and D2S :GKo plus GL1Q2, respectively. These pKd
values are not signi¢cantly di¡erent (Student’s t-test,
Ps 0.05).
3.2. [35S]GTPQS binding assays
The e¡ect of dopamine on the binding of [35S]GTPQS in
di¡erent preparations was determined, as shown in Fig. 2a.
Table 1
Agonist stimulation of [35S]GTPQS binding to D2S :GKo fusion pro-
tein plus GL1Q2
Compound Relative e⁄cacy
(% DA)
pEC50 T S.E.M.
(EC50, nM)
Dopamine 100 5.43T 0.06 (3715)
NPA 154T 9 8.25T 0.06 (5.62)
Bromocriptine 103T 3 8.83T 0.14 (1.48)
(+)-3-PPP 69T 5 4.91T 0.04 (12302)
(3)-3-PPP 17T 1 5.72T 0.20 (1905)
Quinpirole 81T 1 5.74T 0.03 (1820)
m-Tyramine 58T 1 4.91T 0.04 (12302)
p-Tyramine 41T 1 3.82T 0.06 (151356)
Aripiprazole 10T 1 8.84T 0.14 (1.45)
A range of concentrations of each agonist was tested for stimulation
of [35S]GTPQS binding to the D2S :GKo fusion protein expressed with
GL1Q2 as described in Section 2 and the concentration^response
curves analysed to provide the EC50 and the Emax (relative to the
maximal dopamine e¡ect). The basal [35S]GTPQS binding (in the ab-
sence of ligand) amounted to 225T 35 fmol/mg protein. Data shown
are meanTS.E.M. from 4^17 experiments.
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Dopamine had no e¡ect on the binding of [35S]GTPQS to
membranes prepared from non-infected Sf9 cells. When Sf9
cells expressing the D2S :GKo fusion protein were used, dopa-
mine stimulated the binding of [35S]GTPQS in a concentration-
dependent manner, with a maximal e¡ect of 335T 66% over
basal [35S]GTPQS binding and a pEC50 of 5.24 T 0.06 (EC50
5.75 WM), meanTS.E.M., n=4. In the presence of the GL1Q2
complex, the maximal e¡ect of dopamine was increased to
464T 40% and its pEC50 was 5.43T 0.06 (EC50 3.72 WM),
meanTS.E.M., n=17 (Fig. 2a, Table 1). Treatment of Sf9
cells expressing D2S :GKo fusion protein (plus GL1Q2) with
PTX (100 ng/ml, 18 h) did not alter the e¡ect of dopamine.
Several D2 dopamine receptor agonists were tested for their
ability to stimulate the binding of [35S]GTPQS to membranes
prepared from Sf9 cells expressing the D2S :GKo fusion protein
plus GL1Q2 (Fig. 2b). All the compounds tested displayed ag-
onist activity, with NPA and bromocriptine appearing as full
agonists, and the other ligands, including the putative anti-
psychotic drug aripiprazole, behaving as partial agonists (Ta-
ble 1). NPA, bromocriptine and aripiprazole were the most
potent agonists, with EC50 values three orders of magnitude
higher than that of dopamine. Aripiprazole and S-(3)-3-PPP
exhibited low relative e⁄cacies of 10% and 17%, respectively.
We also analysed the e¡ect of other ligands reported to be
antagonists or inverse agonists at D2 dopamine receptors, on
Fig. 1. Expression of D2 dopamine receptors determined by
[3H]spiperone saturation binding. The D2S :GKo fusion protein was
expressed alone or with GL1Q2 in Sf9 cells. Sf9 membranes express-
ing the two preparations were subjected to [3H]spiperone saturation
binding analysis as described in Section 2. The receptor expression
level (Bmax) and the dissociation constant for [3H]spiperone (Kd) are
indicated in the text. Data are representative experiments performed
on each membrane preparation and replicated as shown in the text.
Fig. 2. Modulation of [35S]GTPQS binding in membranes of Sf9 cells
expressing D2S :GKo fusion protein. [35S]GTPQS binding was deter-
mined as described in Section 2. The basal binding of [35S]GTPQS
(in the absence of ligand) amounted to 197T 5 fmol/mg protein and
225T 35 fmol/mg for D2S :GKo and D2S :GKo/GL1Q2, respectively.
a: E¡ect of dopamine at di¡erent preparations. b: E¡ect of D2 re-
ceptor agonists at D2S :GKo plus GL1Q2. c: Inverse agonist e¡ect of
D2 receptor ligands at D2S :GKo plus GL1Q2. Data are from represen-
tative experiments replicated as in Tables 1 and 2.
Table 2
Binding a⁄nity and inverse agonist e¡ects of ligands at D2S :GKo plus GL1Q2
Compound pKi T S.E.M. (Ki, nM) pIC50 T S.E.M. (IC50, nM) Emax (% basal)
(+)-Butaclamol 9.66T 0.27 (0.22) 9.05T0.37 (0.89) 331T 7
Spiperone 9.82T 0.26 (0.15) 9.90T0.27 (0.13) 330T 4
Haloperidol 8.48T 0.16 (3.31) 8.59T0.13 (2.57) 330T 3
Raclopride 7.11T 0.31 (78) 8.48T0.02 (3.31) 328T 4
Clozapine 6.80T 0.15 (158) 7.22T0.14 (60.25) 328T 3
(+)-UH-232 6.80T 0.25 (158) 7.60T0.28 (25.11) 323T 5
Nemonapride 8.95T 0.02 (1.12) 8.27T0.08 (5.37) 319T 1
(+)-AJ76 5.73T 0.07 (1862) 6.53T0.15 (295) 321T 1
Ziprasidone 8.11T 0.05 (7.76) nd 33T 2
(3)-Sulpiride 5.82T 0.12 (1514) na
(3)-Butaclamol 5.24T 0.02 (5754) nd
Binding of ligands was determined in competition experiments versus [3H]spiperone binding to membranes expressing D2S :GKo plus GL1Q2, as
described in Section 2. Competition curves were described best by one binding site models (F-test, P6 0.001) in all cases and Ki values were de-
rived. A range of concentrations of each compound were also tested for e¡ects on [35S]GTPQS binding to the D2S :GKo fusion protein expressed
with GL1Q2 as described in Section 2 and the concentration^response curves analysed to provide the IC50 and the Emax (relative to basal
[35S]GTPQS binding) for the inverse agonists. The basal [35S]GTPQS binding (in the absence of ligand) amounted to 225T 35 fmol/mg protein.
Data shown are meanTS.E.M. from four to seven independent experiments. na=no activity; nd=not determined.
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the binding of [35S]GTPQS to membranes prepared from Sf9
cells expressing the D2S :GKo fusion protein plus GL1Q2. Most
of the ligands tested were able to decrease the basal
[35S]GTPQS binding in a concentration-dependent manner ex-
hibiting di¡erent maximal inhibitions (Emax) and potencies
(Fig. 2c, Table 2). Thus, spiperone, (+)-butaclamol and hal-
operidol showed a maximal inhibition of 330%, whereas nem-
onapride and (+)-UH-232 were less e¡ective. Spiperone, hal-
operidol and nemonapride also displayed higher potencies
than raclopride, UH-232 and (+)-AJ76. (3)-Sulpiride and zi-
prasidone, however, did not have any signi¢cant e¡ect on the
basal [35S]GTPQS binding.
3.3. Competition radioligand binding study
The binding of D2 dopamine receptor agonists to the
D2S :GKo fusion protein expressed in Sf9 cells was investigated
in competition experiments versus [3H]spiperone binding. As
shown in Fig. 3, in the absence of GTP, competition curves
for both dopamine and NPA were ¢tted best by a two binding
site model (F-test, P6 0.001), with higher and lower a⁄nity
binding sites (Kh, Kl). The percentage of higher a⁄nity bind-
ing sites found with the two agonists was comparable (V60%,
Fig. 3, Table 3). In the presence of 100 WM GTP, the com-
petition curves of both agonists were shifted to the right but a
two binding site model still provided the best ¢t (F-test,
P6 0.05). In the presence of GTP, the proportions of higher
a⁄nity binding sites were 40% and 17% for dopamine and
NPA, respectively. The Kh as well as the Kl values of dopa-
mine decreased by one order of magnitude, whereas for NPA
both values were only marginally a¡ected by the presence of
GTP.
A series of D2 dopamine receptor ligands were also tested
for their ability to compete with [3H]spiperone binding to
membranes of Sf9 cells expressing D2S :GKo fusion protein
plus GL1Q2. The competition curves for all the compounds
tested were best ¢tted to a one binding site model (F-test,
P6 0.001, not shown). Spiperone was the most potent com-
petitor, with a pKi of 9.82, a value comparable to the pKd of
[3H]spiperone (see above). Compounds such as (+)-butacla-
mol, haloperidol and nemonapride also exhibited high a⁄nity
for the D2S :GKo/GL1Q2, whereas (3)-butaclamol, (+)-UH-232
and (+)-AJ76 exhibited lower a⁄nity for D2S :GKo/GL1Q2.
4. Discussion
In the present study, we have expressed and characterised a
fusion protein between the D2S dopamine receptor and a GKo
subunit of G protein. The latter was mutated at position 351,
where a cysteine residue was replaced by an isoleucine. Upon
expression in Sf9 cells using baculovirus, we demonstrated
that the fusion protein was functional, by assessing the ability
of dopamine and other D2 receptor agonists to stimulate the
binding of [35S]GTPQS to the D2S :GKo fusion protein. To the
best of our knowledge, this is the ¢rst study to report a func-
tional coupling of a D2 dopamine receptor engaged in a fu-
sion with a GK subunit of G protein.
The D2S :GKo fusion protein expressed in Sf9 cells had a
high a⁄nity for [3H]spiperone and the pKd of this ligand
found in the present study is comparable to that found for
the receptor expressed in other heterologous systems [14,17].
When a series of ligands were used to compete versus the
binding of [3H]spiperone to the D2S :GKo fusion protein, we
found a rank order of binding a⁄nity for the di¡erent ligands
similar to those expected for D2 receptors. Of particular in-
terest was the stereoselectivity of the binding of butaclamol.
Indeed, (3)-butaclamol (the inactive form of the compound)
binds to the D2S :GKo fusion protein with three orders of
magnitude lower a⁄nity compared to (+)-butaclamol (the ac-
tive form of the compound). These results show that the D2S
Fig. 3. Agonist binding to membranes of Sf9 cells expressing
D2S :GKo plus GL1Q2. The binding of dopamine (a) and NPA (b) to
D2S :GKo plus GL1Q2 was determined in competition versus
[3H]spiperone binding in the absence or presence of 100 WM GTP,
as described in Section 2. Data shown are representative experi-
ments replicated as in Table 3 and the curves are the best ¢t curves
to two binding site models.
Table 3
Agonist binding to membranes of Sf9 cells expressing D2S :GKo plus GL1Q2
Dopamine NPA
Control +100 WM GTP Control +100 WM GTP
% Rh 59T 7 41T2 58T 3 17T2
pKh T S.E.M. (Kh, nM) 7.32T 0.36 (48) 5.89T 0.05 (1288) 10.13T 0.13 (0.07) 9.92T 0.12 (0.12)
pKl T S.E.M. (Kl, nM) 5.25T 0.27 (5623) 4.18T 0.04 (66 069) 8.32T 0.08 (5) 7.75T 0.01 (18)
Binding of dopamine and NPA was determined in competition experiments versus [3H]spiperone binding to membranes expressing D2S :GKo
plus GL1Q2, as described in Section 2. Competition curves were described best by two binding site models (F-test, P6 0.002) in all cases and
values for the dissociation constant at the higher (Kh) and lower (Kl) a⁄nity sites and the % higher a⁄nity sites (% Rh) are given. Data are
meanTS.E.M. from four independent experiments.
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receptor engaged in a fusion with the GKo subunit of G pro-
tein is being expressed with ¢delity in Sf9 cells.
Several agonists were then tested for their ability to stim-
ulate [35S]GTPQS binding to membranes expressing D2S :GKo
fusion protein. Dopamine induced a concentration-dependent
stimulation of [35S]GTPQS binding to membranes expressing
the D2S :GKo fusion protein, an e¡ect which was absent in
non-infected Sf9 cells (Fig. 2). Interestingly, when the
D2S :GKo fusion protein was co-expressed with GL1Q2, the
maximal e¡ect of dopamine was signi¢cantly increased.
Thus, the presence of GL1Q2 may modulate the information
transfer between the receptor and its cognate G protein, as
reported by others for a L2-adrenergic receptor/GKs fusion
protein [18]. We, therefore, decided to use the preparation
expressing D2S :GKo fusion protein with GL1Q2 for further
characterisation. As some receptors engaged in a fusion pro-
tein with a cognate G protein subunit have been shown to
interact with other endogenous G proteins [19^21], we sought
to verify the speci¢c activation of the GKo subunit involved in
the fusion protein with the D2S receptor by treating the cells
with PTX. In fact, mutation of the GK subunit of the
G proteins belonging to the Gi=o family at position 351 has
been shown to induce a resistance of the corresponding
G protein to the ADP-ribosylation action of PTX. These mu-
tations have been extensively used in the literature [5,6]. In the
present study, we found similar e¡ects for dopamine for the
stimulation of [35S]GTPQS binding in the presence and in the
absence of PTX. This suggests that the D2S dopamine recep-
tor engaged in the fusion protein is coupling exclusively to the
GKo to which it is fused.
All the compounds tested showed agonist activity in the
preparation expressing D2S :GKo fusion protein with GL1Q2,
with relative e⁄cacies ranging from 10% to up to 150% com-
pared to dopamine. Thus, compounds such as NPA and bro-
mocriptine behaved as full agonists compared to dopamine,
and all the other compounds behaved as partial agonists, in-
cluding aripiprazole (Fig. 2b, Table 1). The potency of the
compounds found in the present study was somewhat lower
than potencies reported for this receptor in other heterologous
systems (see for example [17]). This may re£ect the di¡erences
in the expression system (CHO versus Sf9 cells). However, the
rank order observed for the potency is that expected for D2
receptor activation, with NPA and bromocriptine being the
more potent compounds and p-tyramine showing the lowest
potency.
A range of ligands were also tested for their ability to mod-
ulate the binding of [35S]GTPQS to preparations expressing
D2S :GKo fusion protein with GL1Q2. These included antipsy-
chotic drugs such as clozapine and haloperidol. Interestingly,
most of the compounds tested behaved as inverse agonists at
the D2S :GKo fusion protein. Moreover, di¡erent potencies
could be observed for the di¡erent compounds tested, with
(+)-butaclamol, spiperone and nemonapride appearing as
the most potent inverse agonists. The maximal inhibition lev-
els for these compounds were also variable, with nemonapride
and (+)-AJ76 showing the lower e¡ect. Surprisingly, (+)-UH-
232 behaved as an inverse agonist in the present study. This
compound has been described as a neutral antagonist at the
D2 receptor in some reports [22]. Several studies, however,
reported partial agonist activity for (+)-UH-232 at the D2
dopamine receptor [23^25]. Such a di¡erent range of e⁄cacy
observed for the same ligand acting at one receptor might
re£ect a conformation of the receptor induced by a ligand,
which di¡erentially couples to G proteins. In fact other stud-
ies have used CHO or COS-7 cells expressing the D2 receptor
[22^25]. Indeed the CHO cells express high levels of Gi pro-
teins (Gi2, Gi3) and little Go [26,27]. Thus, (+)-UH-232 might
behave as an inverse agonist when the receptor is interacting
exclusively with Go proteins. However, the interaction of the
D2 receptors with a di¡erent set of G proteins (in particular
Gi proteins) may lead to di¡erent e¡ects observed with (+)-
UH-232. Similarly, we have reported recently the regulation
of G protein selectivity by agonists at rat and human D2L
receptors [13,14]. It is noteworthy that compounds such as
(3)-sulpiride and ziprasidone do not have signi¢cant e¡ects
at the D2S :GKo fusion protein, suggesting that in the presence
of Go, these compounds behave as pure antagonists at the D2
receptor. This may apply to the Gq G protein as well, as in a
recent study using a chimeric D2/K1B receptor, ziprasidone
behaved as a silent antagonist even though the constitutive
activity of the dopamine D2 receptor was increased [25].
Although a fusion protein would be expected to exhibit
agonist binding curves with Hill coe⁄cients close to 1, several
studies have reported higher and lower agonist a⁄nity states
(see for example [3,28] and [5] for a review). In the present
study, when dopamine and NPA were used to compete with
the binding of [3H]spiperone to preparations expressing
D2S :GKo/GL1Q2, the competition data were ¢tted best by
two binding site models. Moreover, the presence of 100 WM
GTP failed to convert the binding curves to a single (low)
a⁄nity state. Furthermore, the percentage of higher a⁄nity
binding sites of NPA was dramatically decreased, whereas
that of dopamine was only marginally a¡ected by the presence
of GTP. Conversely, the a⁄nities of dopamine for both higher
and lower a⁄nity states of the receptor were signi¢cantly
decreased, whereas those of NPA were marginally a¡ected
by the presence of GTP. This di¡erent sensitivity of dopamine
and NPA to GTP may be related to the fusion process. In-
deed, spatial constrains may exist due to the physical prox-
imity and tethering of the carboxy-terminus of the D2S recep-
tor and the NH2 terminus of the GKo. It is also possible that
the mutation of the GK subunit (Cys351Ile) increases the inter-
action of the G protein with the receptor as reported by
others (see [5] for a review). Furthermore, di¡erent conforma-
tions of the same receptor induced by the binding of the two
agonists, as proposed recently [29] and exempli¢ed in several
studies [13,14], could also explain these observations.
In conclusion, this study has described for the ¢rst time the
properties of a fusion protein involving a D2 dopamine recep-
tor and its cognate G protein. Our results show that such a
construct expressed in Sf9 cells exhibits characteristics similar
to those observed in other heterologous systems expressing the
D2 receptor. Interestingly, such a system can be used to char-
acterise both the binding properties and the activity of a range
of ligands (agonists, neutral antagonists, inverse agonists) at
the D2 dopamine receptor. The data obtained in this study,
where the D2 receptor is forced to interact with Go, suggest
that some antipsychotic drugs exhibit di¡erent relative e⁄ca-
cies depending on the particular receptor/G protein combina-
tion. The data may be of additional relevance as in brain the
principal G protein interacting with the D2 receptor is Go [30].
Further fusion constructs between the D2 receptor and other
G proteins may help to clarify the activities of antipsychotic
drugs at the D2 dopamine receptors.
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